Cargando…

CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)

Background: In patients with coronavirus disease 2019 (COVID-19) pneumonia, whether new pulmonary lesions will continue to develop after treatment was unknown. This study aimed to determine whether new pulmonary lesions will develop after treatment in patients with COVID-19 pneumonia, and investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wang Jia, Lv, Zhuo Ma, Lv, Fa Jin, Fu, BinJie, Hu, Liang Bo, Chu, Zhi Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484640/
https://www.ncbi.nlm.nih.gov/pubmed/32922203
http://dx.doi.org/10.7150/ijms.47587
_version_ 1783581012662419456
author Li, Wang Jia
Lv, Zhuo Ma
Lv, Fa Jin
Fu, BinJie
Hu, Liang Bo
Chu, Zhi Gang
author_facet Li, Wang Jia
Lv, Zhuo Ma
Lv, Fa Jin
Fu, BinJie
Hu, Liang Bo
Chu, Zhi Gang
author_sort Li, Wang Jia
collection PubMed
description Background: In patients with coronavirus disease 2019 (COVID-19) pneumonia, whether new pulmonary lesions will continue to develop after treatment was unknown. This study aimed to determine whether new pulmonary lesions will develop after treatment in patients with COVID-19 pneumonia, and investigate their CT features and outcomes. Methods: This retrospective study included 56 consecutive patients with confirmed COVID-19 pneumonia from January 20 to March 5, 2020. Their initial and follow-up CT images and clinical data were reviewed. The CT manifestations of primary and newly developed pulmonary lesions and their changes after treatment were mainly evaluated. Results: Among the 56 patients (mean age: 48±15 years, 35 men) with COVID-19 pneumonia, 42 (75.0%) patients developed new pulmonary lesions during treatment. All new lesions developed before the nucleic acid test turned negative. Patients with new lesions were more likely to have lymphopenia (P=0.041) or increased C-reactive protein (CRP) levels (P<0.001) than those without new lesions. Of the 42 patients, 30 (71.4%) patients developed new lesions once, and 12 (28.6%) twice or thrice, which usually appeared when primary lesions were progressing (37, 88.1%) and 1-15 days after treatment. The newly developed lesions were usually multiple (38, 90.5%), distributed in the previously involved (39, 92.9%) or uninvolved (27, 64.3%) lobes, and manifested as ground-glass opacities (GGOs) with consolidation (23, 54.8%) or pure GGOs (19, 45.2%). After their occurrence, the new lesions in most patients (32, 76.2%) showed direct absorption, whereas those in some patients (10, 23.8%) progressed before absorption. Conclusion: During treatment, most patients with COVID-19 pneumonia will develop new pulmonary lesions, which usually manifest as multiple GGOs distributed around the primary lesions or in previously uninvolved lobes, and are subsequently absorbed directly.
format Online
Article
Text
id pubmed-7484640
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-74846402020-09-12 CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19) Li, Wang Jia Lv, Zhuo Ma Lv, Fa Jin Fu, BinJie Hu, Liang Bo Chu, Zhi Gang Int J Med Sci Research Paper Background: In patients with coronavirus disease 2019 (COVID-19) pneumonia, whether new pulmonary lesions will continue to develop after treatment was unknown. This study aimed to determine whether new pulmonary lesions will develop after treatment in patients with COVID-19 pneumonia, and investigate their CT features and outcomes. Methods: This retrospective study included 56 consecutive patients with confirmed COVID-19 pneumonia from January 20 to March 5, 2020. Their initial and follow-up CT images and clinical data were reviewed. The CT manifestations of primary and newly developed pulmonary lesions and their changes after treatment were mainly evaluated. Results: Among the 56 patients (mean age: 48±15 years, 35 men) with COVID-19 pneumonia, 42 (75.0%) patients developed new pulmonary lesions during treatment. All new lesions developed before the nucleic acid test turned negative. Patients with new lesions were more likely to have lymphopenia (P=0.041) or increased C-reactive protein (CRP) levels (P<0.001) than those without new lesions. Of the 42 patients, 30 (71.4%) patients developed new lesions once, and 12 (28.6%) twice or thrice, which usually appeared when primary lesions were progressing (37, 88.1%) and 1-15 days after treatment. The newly developed lesions were usually multiple (38, 90.5%), distributed in the previously involved (39, 92.9%) or uninvolved (27, 64.3%) lobes, and manifested as ground-glass opacities (GGOs) with consolidation (23, 54.8%) or pure GGOs (19, 45.2%). After their occurrence, the new lesions in most patients (32, 76.2%) showed direct absorption, whereas those in some patients (10, 23.8%) progressed before absorption. Conclusion: During treatment, most patients with COVID-19 pneumonia will develop new pulmonary lesions, which usually manifest as multiple GGOs distributed around the primary lesions or in previously uninvolved lobes, and are subsequently absorbed directly. Ivyspring International Publisher 2020-08-29 /pmc/articles/PMC7484640/ /pubmed/32922203 http://dx.doi.org/10.7150/ijms.47587 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Li, Wang Jia
Lv, Zhuo Ma
Lv, Fa Jin
Fu, BinJie
Hu, Liang Bo
Chu, Zhi Gang
CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)
title CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)
title_full CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)
title_fullStr CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)
title_full_unstemmed CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)
title_short CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)
title_sort ct features and outcomes of newly developed pulmonary lesions in patients with coronavirus disease 2019 (covid-19)
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484640/
https://www.ncbi.nlm.nih.gov/pubmed/32922203
http://dx.doi.org/10.7150/ijms.47587
work_keys_str_mv AT liwangjia ctfeaturesandoutcomesofnewlydevelopedpulmonarylesionsinpatientswithcoronavirusdisease2019covid19
AT lvzhuoma ctfeaturesandoutcomesofnewlydevelopedpulmonarylesionsinpatientswithcoronavirusdisease2019covid19
AT lvfajin ctfeaturesandoutcomesofnewlydevelopedpulmonarylesionsinpatientswithcoronavirusdisease2019covid19
AT fubinjie ctfeaturesandoutcomesofnewlydevelopedpulmonarylesionsinpatientswithcoronavirusdisease2019covid19
AT huliangbo ctfeaturesandoutcomesofnewlydevelopedpulmonarylesionsinpatientswithcoronavirusdisease2019covid19
AT chuzhigang ctfeaturesandoutcomesofnewlydevelopedpulmonarylesionsinpatientswithcoronavirusdisease2019covid19